161 related articles for article (PubMed ID: 11728222)
1. Theratope vaccine (STn-KLH).
Holmberg LA; Sandmaier BM
Expert Opin Biol Ther; 2001 Sep; 1(5):881-91. PubMed ID: 11728222
[TBL] [Abstract][Full Text] [Related]
2. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
[TBL] [Abstract][Full Text] [Related]
3. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
Miles D; Papazisis K
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccine THERATOPE- Biomira.
Adis International Ltd
Drugs R D; 2003; 4(4):236-40. PubMed ID: 12848588
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
MacLean GD; Miles DW; Rubens RD; Reddish MA; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):309-16. PubMed ID: 8877724
[TBL] [Abstract][Full Text] [Related]
7. Clinical development of the STn-KLH vaccine (Theratope).
Ibrahim NK; Murray JL
Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with Theratope (STn-KLH) as treatment for breast cancer.
Holmberg LA; Sandmaier BM
Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine.
Holmberg LA; Oparin DV; Gooley T; Lilleby K; Bensinger W; Reddish MA; MacLean GD; Longenecker BM; Sandmaier BM
Bone Marrow Transplant; 2000 Jun; 25(12):1233-41. PubMed ID: 10871727
[TBL] [Abstract][Full Text] [Related]
10. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine.
Sandmaier BM; Oparin DV; Holmberg LA; Reddish MA; MacLean GD; Longenecker BM
J Immunother; 1999 Jan; 22(1):54-66. PubMed ID: 9924700
[TBL] [Abstract][Full Text] [Related]
11. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
[TBL] [Abstract][Full Text] [Related]
12. Technology evaluation: Theratope, Biomira Inc.
Morse MA
Curr Opin Mol Ther; 2000 Aug; 2(4):453-8. PubMed ID: 11249777
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
[TBL] [Abstract][Full Text] [Related]
14. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
[TBL] [Abstract][Full Text] [Related]
15. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.
Julien S; Picco G; Sewell R; Vercoutter-Edouart AS; Tarp M; Miles D; Clausen H; Taylor-Papadimitriou J; Burchell JM
Br J Cancer; 2009 Jun; 100(11):1746-54. PubMed ID: 19436292
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
[TBL] [Abstract][Full Text] [Related]
17. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
18. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
19. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
20. A rat model to study the role of STn antigen in colon cancer.
Ogata S; Ho I; Maklansky J; Chen A; Werther JL; Reddish M; Longenecker BM; Sigurdson E; Iishi S; Zhang JY; Itzkowitz SH
Glycoconj J; 2001; 18(11-12):871-82. PubMed ID: 12820721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]